Answers are grounded in this paper and cite their sources.
Case-control study reveals elevated CCR2+ non-classical monocytes distinguish HER2-negative breast cancer patients, suggesting a viable liquid biopsy biomarker for early diagnosis.
HER2-negative breast cancers, particularly triple-negative (TNBC) and luminal B (LB) variants, require novel biomarkers for rapid diagnostic confirmation due to their aggressive nature and radiological challenges. This pilot study evaluated whether subset-specific CCR2 expression on peripheral monocytes could serve as a high-fidelity liquid biopsy biomarker. We analyzed monocyte subsets-classical (CD14++CD16-), intermediate (CD14++CD16+), and non-classical (CD14 + CD16++)-via flow cytometry in 60 HER2-negative breast cancer patients and 30 healthy controls. Results identified a significant systemic remodeling of the monocyte lineage. A dramatic, nearly four-fold increase in CCR2 expression was observed within the non-classical subset (18.32% vs. 4.29% in controls; p < 0.001). ROC analysis demonstrated that the percentage of CCR2+ non-classical monocytes distinguished cancer patients with 96% sensitivity and 96% specificity. Notably, this immunophenotypic shift was independent of tumor stage, grade, and systemic inflammatory markers. These findings suggest that 'inducible' non-classical monocytes could serve as a specific hallmark of early-stage HER2-negative breast cancer, potentially providing a minimally invasive tool for early diagnosis.
No takes yet. Share an insight, caveat, or question.
Budzyń et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: